Optimizing phase II clinical trials: novel trial designs

Anastasia Ivanova, Bahjat Qaqish, David A. Schoenfeld, Optimality, sample size, and power calculations for the sequential parallel comparison design. Statistics in Medicine. ,vol. 30, pp. 2793- 2803 ,(2011) , 10.1002/SIM.4292

Maurizio Fava, David Mischoulon, Dan Iosifescu, Janet Witte, Michael Pencina, Martina Flynn, Linda Harper, Michael Levy, Karl Rickels, Mark Pollack, A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychotherapy and Psychosomatics. ,vol. 81, pp. 87- 97 ,(2012) , 10.1159/000332050

Yeh-Fong Chen, Yang Yang, H.M. James Hung, Sue-Jane Wang, Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials. Contemporary Clinical Trials. ,vol. 32, pp. 592- 604 ,(2011) , 10.1016/J.CCT.2011.04.006

David A. Schoenfeld, Merit Cudkowicz, Design of phase II ALS clinical trials Amyotrophic Lateral Sclerosis. ,vol. 9, pp. 16- 23 ,(2008) , 10.1080/17482960701875896

Werner Brannath, Hans Ulrich Burger, Ekkehard Glimm, Nigel Stallard, Marc Vandemeulebroecke, Gernot Wassmer, Comments on the draft guidance on “Adaptive design clinical trials for drugs and biologics” of the U.S. Food and Drug Administration Journal of Biopharmaceutical Statistics. ,vol. 20, pp. 1125- 1131 ,(2010) , 10.1080/10543406.2010.514453

R. M. Christley, Power and Error: Increased Risk of False Positive Results in Underpowered Studies The Open Epidemiology Journal. ,vol. 3, pp. 16- 19 ,(2010) , 10.2174/1874297101003010016